Geographic coverage
FDA compliance consulting by location
Tailwind Pharma works with pharmaceutical manufacturers, CDMOs, and biotechnology companies in the markets below. Each page includes local context, service pillars, and answers to the questions companies in that area ask most often.
FDA compliance consulting, 483 response, Warning Letter remediation, and mock inspections for pharmaceutical and CDMO sites across Arizona. View the Arizona page.
FDA compliance consulting, 483 response, Warning Letter remediation, and mock inspections for pharmaceutical and CDMO sites across Arkansas. View the Arkansas page.
FDA compliance consulting, 483 response, Warning Letter remediation, and mock inspections for pharmaceutical and CDMO sites across California. View the California page.
FDA compliance consulting, 483 response, Warning Letter remediation, and mock inspections for pharmaceutical and CDMO sites across Colorado. View the Colorado page.
FDA compliance consulting, 483 response, Warning Letter remediation, and mock inspections for pharmaceutical and CDMO sites across Florida. View the Florida page.
FDA compliance consulting, 483 response, Warning Letter remediation, and mock inspections for pharmaceutical and CDMO sites across Illinois. View the Illinois page.
FDA compliance consulting, 483 response, Warning Letter remediation, and mock inspections for pharmaceutical and CDMO sites across Iowa. View the Iowa page.
FDA compliance consulting, 483 response, Warning Letter remediation, and mock inspections for pharmaceutical and CDMO sites across Kansas. View the Kansas page.
FDA compliance consulting, 483 response, Warning Letter remediation, and mock inspections for pharmaceutical and CDMO sites across Missouri. View the Missouri page.
FDA compliance consulting, 483 response, Warning Letter remediation, and mock inspections for pharmaceutical and CDMO sites across Nebraska. View the Nebraska page.
FDA compliance consulting, 483 response, Warning Letter remediation, and mock inspections for pharmaceutical and CDMO sites across Nevada. View the Nevada page.
FDA compliance consulting, 483 response, Warning Letter remediation, and mock inspections for pharmaceutical and CDMO sites across New Jersey. View the New Jersey page.
FDA compliance consulting, 483 response, Warning Letter remediation, and mock inspections for pharmaceutical and CDMO sites across New Mexico. View the New Mexico page.
FDA compliance consulting, 483 response, Warning Letter remediation, and mock inspections for pharmaceutical and CDMO sites across Ohio. View the Ohio page.
FDA compliance consulting, 483 response, Warning Letter remediation, and mock inspections for pharmaceutical and CDMO sites across Pennsylvania. View the Pennsylvania page.
FDA compliance consulting, 483 response, Warning Letter remediation, and mock inspections for pharmaceutical and CDMO sites across Tennessee. View the Tennessee page.
FDA compliance consulting, 483 response, Warning Letter remediation, and mock inspections for pharmaceutical and CDMO sites across Texas. View the Texas page.
FDA compliance consulting, 483 response, Warning Letter remediation, and mock inspections for pharmaceutical and CDMO sites across Utah. View the Utah page.
FDA compliance consulting, 483 response, Warning Letter remediation, and mock inspections for pharmaceutical and CDMO sites across Wyoming. View the Wyoming page.
Don't see your city?
Tailwind Pharma supports US and non-US sites remotely and on site. If your market is not listed, the same triage call applies.